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Daptomycin in combination with surgical therapy has shown to be effective for treatment of deep sternal wound
infection in cardiac surgery. However, till now midterm results in terms of re-infection or re-operation in patients
who were successfully treated with daptomycin for gram-positive deep sternal wound infection are not published.
Herein, we present midterm results in patients treated successfully with daptomycin after cardiac surgery.
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Methods
This follow up study includes 23 patients. These patients
were treated in the past with daptomycin combined with
multiple surgeries for deep sternal wound infection
(DSWI) due to gram-positive organisms. The initial sur-
veillance was achieved in 100% and wound healing was
successfully established in all patients at the time of dis-
charge for the initial clinical course [1]. After discharge,
all patients were followed up in terms of mortality, re-
infection, and re-operation.
Results
None of the patients were lost to follow up and follow-up
time ranged from 3–42 months (mean 26 months, cumu-
lative 598 patient-months). Four patients (17%) died dur-
ing the follow up. Three of them died within 3 months of
discharge; one due to mitral valve endocarditis, one due
to urosepsis, and cause of death could not be established
in one. The last patient died after 24 months and cause of
death could not be established in him as well. No docu-
mented wound complications occurred in any of these
patients from the time of discharge till their death.
Two patients (8.5%) after discharge developed superfi-
cial wound complications, which were treated surgically.* Correspondence: Popov@med.uni-goettingen.de
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and postoperatively developed a DSWI with a Staphylo-
coccus aureus and was discharged after 4 weeks in a
good clinical condition. Thirty-two months after dis-
charge, he developed superficial wound dehiscence, how-
ever without any microbial infection.
Other patient had a coronary artery bypass grafting
combined with aortic valve replacement. Postoperatively,
he developed a DSWI with Staphylococcus aureus methi-
cillin susceptible, and after treatment with daptomycin and
negative pressure wound therapy (NPWT), a complete
wound healing was achieved. Twenty-nine months after
discharge, the patient was presented again with a superfi-
cial wound dehiscence. The wound culture was positive
for Staphylococcus aureus methicillin susceptible and the
patient was colonized completely. Following multiple sur-
geries, decolonization and NPWT the patient was dis-
charged home in a good clinical condition. The survival
and the requirement for re-operation are summarized in
Figure 1.Comment
DSWI after cardiac surgery with sternotomy is still a ser-
ious surgical challenge. Several treatment options are
described in the literature to deal with this complication. A
wide range of strategies have been proposed for the treat-
ment of DSWI, including an intense course of directed
antibiotic therapy together with a series of debridements. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Survival and Freedom from Reintervention.
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the optimal antibiotic management or duration of therapy
for DSWI is scarce. Daptomycin has shown to be effective
combined with multiple surgeries for treatment of DSWI
in cardiac surgery [1,3,4]. However, up till now, no study
has shown midterm results in terms of re-infection or re-
operation for patients who were successfully treated with
daptomycin for gram-positive DSWI.
We have published our results of prospective study
about treatment of gram-positive DSWI with daptomycin
for cardiac surgery patients performed between February
2009 and September 2010 [1]. Twenty-three consecutive
patients with post-sternotomy mediastinitis from gram-
positive organisms (out of 1574 primary sternotomies)
were identified and treated with intravenous daptomycin
with acceptable mortality and morbidity. However, the
major drawback of our study was limited observation
period lacking any information regarding post-discharge
re-infection or re-operation.
Herein, we present our results of discharged patient’s
outcome which were treated successfully with daptomy-
cin after cardiac surgery in a midterm follow up.
We had no recurrence of DSWI, which is observed oc-
casionally after cardiac surgery [5]. However, we had one
case with superficial wound infection with Staphylococ-
cus aureus methicillin susceptible which was treated suc-
cessfully again with daptomycin.
Also, the mortality in the follow up in patients with
DSWI was not different compared to contemporary
study [5]. This follow up study confirms that daptomycin
can be considered as a viable treatment option for surgi-
cal management of gram-positive DSWI after cardiac
surgery combined with surgical therapy. Our series pre-
sents several limitations; mainly lack of randomization
and a small cohort. Further studies are warranted to
confirm our single centre experience with daptomycin in
treatment of gram-positive DSWI.Competing interests
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